Morpholino

MO4-tal1

ID

ZDB-MRPHLNO-050527-2

Name

MO4-tal1

Previous Names

SclMO (1)
scl E2/IMO (1)
scl spliceMO (1)

Target

tal1 (1)

Sequence

5' - AATGCTCTTACCATCGTTGATTTCA - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

Targets exon/intron boundary sequence of exon 3/intron 3.

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO4-tal1

No data available

Phenotype

Phenotype resulting from MO4-tal1

Phenotype	Fish	Figures
blood vasculature lacks parts or has fewer parts of type blood vessel, abnormal	s843Tg + MO4-tal1	Fig. S5 from Reischauer et al., 2016
caudal vein plexus EGFP expression decreased amount, abnormal	s843Tg + MO4-tal1	Fig. S5 from Reischauer et al., 2016
embryonic hemopoiesis disrupted, abnormal	AB + MO4-tal1	Fig. 4 from Liu et al., 2008
endocardium spi1b expression increased amount, abnormal	WT + MO4-tal1	Fig. 4 from Capon et al., 2022
endocardium EGFP expression increased amount, abnormal	WT + MO4-tal1	Fig. 4 from Capon et al., 2022
endocardium myl7 expression increased amount, abnormal	WT + MO4-tal1	Fig. 4 from Capon et al., 2022
endocardium myl7 expression spatial pattern, abnormal	WT + MO4-tal1	Fig. 4 from Capon et al., 2022
endocardium spi1b expression spatial pattern, abnormal	WT + MO4-tal1	Fig. 4 from Capon et al., 2022
endocardium EGFP expression spatial pattern, abnormal	WT + MO4-tal1	Fig. 4 from Capon et al., 2022
heart edematous, abnormal	WT + MO4-tal1	Fig. S6 from Hall et al., 2007
intersegmental vessel EGFP expression absent, abnormal	s843Tg + MO4-tal1	Fig. S5 from Reischauer et al., 2016
myeloid cell absent, abnormal	WT + MO4-tal1	Fig. S6 from Hall et al., 2007
posterior lateral mesoderm morphology, abnormal	AB + MO4-tal1	Fig. 4 from Liu et al., 2008

Phenotype of all Fish created by or utilizing MO4-tal1

Phenotype	Fish	Conditions	Figures
posterior lateral mesoderm morphology, abnormal	AB + MO4-tal1	standard conditions	Fig. 4 from Liu et al., 2008
embryonic hemopoiesis disrupted, abnormal	AB + MO4-tal1	standard conditions	Fig. 4 from Liu et al., 2008
endocardium myl7 expression spatial pattern, abnormal	WT + MO4-tal1	standard conditions	Fig. 4 from Capon et al., 2022
endocardium EGFP expression spatial pattern, abnormal	WT + MO4-tal1	standard conditions	Fig. 4 from Capon et al., 2022
myeloid cell absent, abnormal	WT + MO4-tal1	standard conditions	Fig. S6 from Hall et al., 2007
endocardium EGFP expression increased amount, abnormal	WT + MO4-tal1	standard conditions	Fig. 4 from Capon et al., 2022
endocardium myl7 expression increased amount, abnormal	WT + MO4-tal1	standard conditions	Fig. 4 from Capon et al., 2022
endocardium spi1b expression spatial pattern, abnormal	WT + MO4-tal1	standard conditions	Fig. 4 from Capon et al., 2022
heart edematous, abnormal	WT + MO4-tal1	standard conditions	Fig. S6 from Hall et al., 2007
endocardium spi1b expression increased amount, abnormal	WT + MO4-tal1	standard conditions	Fig. 4 from Capon et al., 2022
blood vasculature lacks parts or has fewer parts of type blood vessel, abnormal	s843Tg + MO4-tal1	standard conditions	Fig. S5 from Reischauer et al., 2016
caudal vein plexus EGFP expression decreased amount, abnormal	s843Tg + MO4-tal1	standard conditions	Fig. S5 from Reischauer et al., 2016
intersegmental vessel EGFP expression absent, abnormal	s843Tg + MO4-tal1	standard conditions	Fig. S5 from Reischauer et al., 2016
heart primordium nkx2.5 expression amount, ameliorated	atf3^{zf3482/zf3482} + MO4-tal1	standard conditions	Fig. 4 from Yin et al., 2020
atrium size, ameliorated	atf3^{zf3482/zf3482}; fb7Tg + MO4-tal1	standard conditions	Fig. 4 from Yin et al., 2020
vascular endothelium mCherry expression spatial pattern, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	standard conditions	Fig. 4 from Metikala et al., 2022
vascular endothelium damaged, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression spatial pattern, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression decreased amount, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression spatial pattern, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression spatial pattern, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	standard conditions	Fig. 4 from Metikala et al., 2022
vascular endothelium morphogenesis of a branching structure decreased process quality, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	standard conditions	Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression decreased amount, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	standard conditions	Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression decreased amount, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium regeneration decreased process quality, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	chemical treatment by environment: metronidazole	Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression decreased amount, abnormal	etsrp^ci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1	standard conditions	Fig. 4 from Metikala et al., 2022

Citations